← Oncology Approval Tracker

FDA DECISION ·

Adstiladrin

nadofaragene firadenovec-vncg · Ferring Pharmaceuticals

FDA approvalNew therapyBladder cancer
Open LinkedIn brief ↓

1 min read · estimated

Sources

APPROVED USE

What FDA approved

Adults with high-risk, BCG-unresponsive non-muscle-invasive bladder cancer with carcinoma in situ, with or without papillary tumors.

LAMPGEN ANALYSIS

Why it matters

An intravesical gene therapy expands bladder-preserving options after BCG failure for patients with carcinoma in situ.

What research teams should watch

Verify the BCG record and carcinoma in situ pathology, then coordinate administration and cystoscopic surveillance.

PRIMARY RECORDS

Sources